| Autor: |
Naimo E; Institute of Virology, Hannover Medical School, 30625 Hannover, Germany.; German Centre for Infection Research, Hannover-Braunschweig Site, 38023 Braunschweig, Germany., Zischke J; Institute of Virology, Hannover Medical School, 30625 Hannover, Germany.; German Centre for Infection Research, Hannover-Braunschweig Site, 38023 Braunschweig, Germany., Schulz TF; Institute of Virology, Hannover Medical School, 30625 Hannover, Germany.; German Centre for Infection Research, Hannover-Braunschweig Site, 38023 Braunschweig, Germany.; Cluster of Excellence 2155 RESIST, Institute of Virology, Hannover Medical School, 30625 Hannover, Germany. |
| Abstrakt: |
Kaposi-sarcoma-associated herpesvirus (KSHV) or human herpesvirus 8 (HHV-8) is the causative agent of several malignancies, including Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD). Active KSHV replication has also been associated with a pathological condition called KSHV inflammatory cytokine syndrome (KICS), and KSHV may play a role in rare cases of post-transplant polyclonal lymphoproliferative disorders. Several commonly used herpesviral DNA polymerase inhibitors are active against KSHV in tissue culture. Unfortunately, they are not always efficacious against KSHV-induced diseases. To improve the outcome for the patients, new therapeutics need to be developed, including treatment strategies that target either viral proteins or cellular pathways involved in tumor growth and/or supporting the viral life cycle. In this review, we summarize the most commonly established treatments against KSHV-related diseases and review recent developments and promising new compounds that are currently under investigation or on the way to clinical use. |
